Bepranemab
3 trials in this asset. Source: ClinicalTrials.gov, as of July 21, 2026.
Trials
3
Ongoing
1
Recruiting
0
Completed
2
Sites
127
Countries
10
Endpoints
13
Composite endpoints
0
Distinct sites and countries across this asset's trials. A site running several of its trials counts once, matching the map. All 13 linked ClinicalTrials.gov endpoints are classified into the categories below. Trial and endpoint linkage does not by itself establish treatment attribution for every endpoint.
Development
Where the program stands
Trials by phase
Trials by status
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Most-measured metrics
Top 20 metrics across this asset's endpoints
Normalized metric codes are available for 3 of 13 classified ClinicalTrials.gov endpoints for this asset; the ranking below covers that coded subset.
1
1
1
Trials
Trials for this asset
Every trial for this asset, with the same search, filters, and sort as the Trials tab.
3 of 3
| Asset / Disease area | Key I/E criterion | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| NCT04867616A Study to Test the Efficacy, Safety, and Tolerability of Bepranemab (UCB0107) in Patients With Mild Cognitive Impairment or Mild Alzheimer's Disease (AD) | Bepranemab Alzheimer’s disease, MCI / preclinical Alzheimer’s | mild AD dementia | Ph 2 | Completed | 103 | May 2024 | - | |
| NCT04185415A Study to Test the Safety and Tolerability of UCB0107 in Study Participants With Progressive Supranuclear Palsy (PSP) | Bepranemab Frontotemporal dementia | Study partner/caregiver required | Ph 1 | Completed | 13 | Nov 2021 | - | |
| NCT04658199A Study to Test the Safety and Tolerability of Long-term UCB0107 Administration in Study Participants With Progressive Supranuclear Palsy | Bepranemab Frontotemporal dementia | Age ≥40 | Ph 1 | Active, not recruiting | 11 | Dec 2027 | - |
Showing 1-3 of 3 trials